Seroquel (Quetiapine): Indications, Dosing, and Monitoring
FDA-Approved Indications
Seroquel is FDA-approved for schizophrenia (adults and adolescents 13-17 years), bipolar mania (adults and children 10-17 years), bipolar depression (adults only), and maintenance treatment of bipolar I disorder as adjunct therapy 1.
Specific Approved Uses:
- Schizophrenia: Adults and adolescents (13-17 years)
- Bipolar I disorder, manic episodes: Monotherapy or adjunct to lithium/divalproex in adults; monotherapy in children/adolescents (10-17 years)
- Bipolar depression: Adults only
- Bipolar I maintenance: Adjunct to lithium/divalproex in adults
Dosing Regimens by Indication
Schizophrenia - Adults 1
- Day 1: 25 mg twice daily
- Day 2: 25-50 mg twice daily (total 50-100 mg/day)
- Day 3: Increase to 100-200 mg twice daily (total 200-400 mg/day)
- Day 4: Target 300-400 mg/day
- Recommended dose range: 150-750 mg/day
- Maximum: 750 mg/day
- Further adjustments in 25-50 mg increments, no more frequently than every 2 days
Schizophrenia - Adolescents (13-17 years) 1
- Day 1: 25 mg twice daily (50 mg/day)
- Day 2: 100 mg/day (divided twice daily)
- Day 3: 200 mg/day
- Day 4: 300 mg/day
- Day 5: 400 mg/day
- Recommended dose range: 400-800 mg/day
- Maximum: 800 mg/day
- May be given three times daily based on response
Bipolar Mania - Adults 1
- Day 1: 100 mg/day (divided twice daily)
- Day 2: 200 mg/day
- Day 3: 300 mg/day
- Day 4: 400 mg/day
- Recommended dose range: 400-800 mg/day
- Maximum: 800 mg/day
- Further adjustments up to 800 mg/day by Day 6 in increments ≤200 mg/day
Bipolar Mania - Children/Adolescents (10-17 years) 1
- Day 1: 25 mg twice daily (50 mg/day)
- Day 2: 100 mg/day
- Day 3: 200 mg/day
- Day 4: 300 mg/day
- Day 5: 400 mg/day
- Recommended dose range: 400-600 mg/day
- Maximum: 600 mg/day
Bipolar Depression - Adults 1
- Administer once daily at bedtime
- Day 1: 50 mg
- Day 2: 100 mg
- Day 3: 200 mg
- Day 4: 300 mg
- Target and maximum dose: 300 mg/day
Special Population Dosing Adjustments
Elderly Patients 1
Start at 50 mg/day with slower titration due to increased risk of hypotension and falls 2. Increase in 50 mg/day increments based on clinical response and tolerability. A 2025 study found low-dose quetiapine in older adults was associated with significantly higher mortality (HR 3.1), dementia (HR 8.1), and falls (HR 2.8) compared to trazodone 2.
Hepatic Impairment 1
Start at 25 mg/day. Increase daily in 25-50 mg/day increments to effective dose based on response and tolerability.
CYP3A4 Inhibitor Co-administration 1, 3
Reduce quetiapine dose to one-sixth (1/6) of original dose when co-administered with potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, nefazodone). When the inhibitor is discontinued, increase quetiapine dose 6-fold back to original dose. This is particularly critical with HIV protease inhibitors—failure to reduce dose has resulted in coma 3.
Off-Label Uses (Not FDA-Approved)
While quetiapine is commonly used off-label for various conditions, a 2024 systematic review found that 79% of off-label indications studied lacked confirmatory large randomized trials within 5 years of initial exploratory studies 4. Off-label uses include:
- Alzheimer's disease behavioral symptoms: 12.5 mg twice daily initially, maximum 200 mg twice daily; more sedating with risk of orthostatic hypotension 5
- ICU delirium: Guidelines suggest use, though evidence for BID vs bedtime dosing shows no significant difference in delirium recovery 6, 7
- Insomnia: Commonly prescribed but NOT recommended—associated with increased mortality, dementia, and falls in older adults 2
Monitoring Recommendations
Baseline (Before Starting) 8
- BMI and waist circumference
- Blood pressure
- HbA1c or fasting glucose
- Lipid panel
- Prolactin level
- Liver function tests
- Renal function (urea and electrolytes)
- Complete blood count
- Electrocardiogram (assess QTc interval)
During Titration 8
- Fasting glucose: Recheck at 4 weeks (if fasting not possible, use random glucose as screening)
- BMI, waist circumference, blood pressure: Weekly for 6 weeks
Ongoing Monitoring 8
- All baseline parameters: Repeat at 3 months, then annually
- Anticholinergic burden assessment: Quetiapine has high central anticholinergic activity 8
- QTc monitoring: Particularly important when combining with other QTc-prolonging medications 9
Key Safety Considerations
Critical Warnings
- Black Box Warning: Increased mortality in elderly patients with dementia-related psychosis 1
- Suicidality risk: Monitor closely in all ages, especially when initiating therapy 1
- Orthostatic hypotension: Particularly problematic in elderly; monitor blood pressure during titration 5
- Metabolic effects: Weight gain, hyperglycemia, dyslipidemia—quetiapine has moderate metabolic risk 8
- Sedation: Dose-dependent; consider timing of administration 5
- Anticholinergic effects: High central anticholinergic activity may worsen cognitive function 8
Drug Interactions
Avoid or use extreme caution with QTc-prolonging medications 9. Dose reduction mandatory with strong CYP3A4 inhibitors 1, 3.
Practical Dosing Considerations
The therapeutic dose range for schizophrenia is broad (150-750 mg/day), but fixed-dose studies suggest 150-450 mg/day is as effective as higher doses 10. A 2008 review concluded that standard dosing ranges are appropriate and evidence does not support routine use of doses >800 mg/day 10. However, individual patients may require dose adjustments within the approved range based on response and tolerability 11, 12, 13.
For bipolar depression, the target dose is specifically 300 mg/day at bedtime—this is both the recommended and maximum dose for this indication 1.